HER2 Over Expression in Malignant Palpable Breast Lumps of Pre and Postmenopausal Women Attending RICK.
الملخص
Back ground: Human Epidermal growth factor Receptor 2 (HER-2/neu) over expression in breast
cancer is associated with poor outcome and decrease disease free survival (DFS). The aim of this
study was to evaluate the over expression of HER2/neu among premenopausal and postmenopausal
females presented with malignant palpable breast lumps to Radio Isotope Center Khartoum (RICK).
Methods: The study was a case-control conducted among patients attending Radiation Isotopes
Centre Khartoum (RICK). A total of 328 women were randomly selected. Data were collected by a
pre coded, pre tested questionnaire. Tissue biopsies of breast lumps had been analyzed using
immunohistochemical techniques for HERR-2/neu over expression and its relation to other
prognostic factors was evaluated.
Results: HER-2/neu + vein first pregnancy at ≥ 23 years, were 32 (41%) in the cases, 6 (35%) in
the controls of premenopausal women, and 21(44%) in the cases, 5 (38%) in the controls of
postmenopausal women. HER-2/neu + veexpression in relation to age at menarche ≤ 12 years was
39 (51%) in the cases, 7(39%) in the controls of premenopausal women, and 36 (56%) in the cases,
7 (45%) in the controls of postmenopausal women. HER-2/neu+ vein relation to Body Mass Index
> 29 kg/m2
showed 7 (37%) in the cases, 2 (33%) in the controls of premenopausal women
(x2=0.024), and 8(38%) in the cases, 2(40%) in the controls of postmenopausal women (x2=
0.006). HER-2/neu+ veexpression in relation to history of abortion or miscarriage (ever) was found
to be 21 (39%) in the cases, 4 (33%) in the controls of premenopausal women, and 18 (44%) in the
cases, 3 (33%) in the controls among postmenopausal women. HER-2/neu+ veexpression in relation
to the history of breast cancer in a first degree relatives was 3 (25%) in the cases, 1(50%) in the
controls of premenopausal women, and 4 (22%) in the cases, 2 (28%) in the controls of
postmenopausal women. HER-2/neu+ veexpression in relation to the use of oral contraceptives was
3 (37%) in the cases, 1(50%) in the controls among premenopausal women, and 3 (27%) in the
cases, 1 (50%) in the controls of postmenopausal women.
Conclusion: The study confirmed an etiological association between HER2/neu+ve and HER2/neu
– ve and age at first pregnancy ≥ 23 years, age of menarche at ≤ 12 years, abortion or miscarriage in
premenopausal and postmenopausal Sudanese women, while an etiological association was
confirmed between HER2/neu+ve and HER2/neu –ve, and BMI in premenopausal women, and the
family history of cancer in pos menopausal women.
المراجع
2. Underwood JCE. General and systematic pathology, 2nd ed. Churchill Livingstone; 1996. PP . 82.
3. Hall JM, Lee MK, Newman B, et al.: Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250(4988): 1684-1689, 1990.
4. Taucher S, Rudas M, Mader RM et al.: Do we need HER-2/neu testing for all patients with primary breast carcinoma .Cancer 2003, 98:2547-2553.
5. Revillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998, 34:791-808.
6. Ross JS, Fletcher JA, Linette GP et al. The Her2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003, 8:307-325.
7. Olsson H, Borg A, Ferno M et al. Her-2/neu and INT2 proto- oncogene amplification in malignant breast tumours in relation to reproductive factors and exposure to exogenous hormones. J NatI Cancer Inst, 1999, 83: 1483- 1487.
8. Treurniet HF, Rookus MA, Petrese HL et al. Differences in breast cancer risk factors to neu ( cerbB2) protein overexpression of the breast tumor. Cancer Res 1992, 52: 2344 – 2345.
9. Liberman L, Dershaw DD, Rosen PP et al. Stereotaxic core biopsy of impalpable spiculated breast masses. AJR Am. J Roentgenol 1995;165:551–554.
10. Huang WY, Newman B, Millikan RC et al. Risk of breast cancer according to the status of HER2/ neu oncogene amplification. Cancer Epidemiol Biomarkers Prev 2000, 9: 65-71.
11. Vlachonikolis IG, Aletra TJ, Georgoulias V: Incidence of breast cancer on Crete, 1994 – 1995. Eur J Cancer 2002, 38: 574 – 577.
12. Gammon MD, Hibshoosh H, Terry MB, Bose S et al. Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev 1999, 8: 413 – 419.
